e-learning
resources
Munich 2014
Sunday, 07.09.2014
Environment and mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clara cell protein 16 (CC16) and markers of fibrosis in exogenous toxic (ETA) and exogenous allergic (EAA) alveolites
G. Orlova, E. Surkova (Saint-Petersburg, Russian Federation)
Source:
International Congress 2014 – Environment and mechanisms
Session:
Environment and mechanisms
Session type:
Thematic Poster Session
Number:
1099
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Orlova, E. Surkova (Saint-Petersburg, Russian Federation). Clara cell protein 16 (CC16) and markers of fibrosis in exogenous toxic (ETA) and exogenous allergic (EAA) alveolites. Eur Respir J 2014; 44: Suppl. 58, 1099
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Related content which might interest you:
A mechanism for acceleration of GM-CSF autoantibody (GMAb) production in autoimmune pulmonary alveolar proteinosis (aPAP)
Source: International Congress 2014 – Molecular pathogenesis of pulmonary inflammatory diseases (COPD, asthma and ILD)
Year: 2014
Chemical and hard metal induced exogenous toxic alveolitis (ETA) (follow up 1,5 years)
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Alveolomucin and KL6 as markers of exogenous alveolitis progression
Source: International Congress 2014 – Environment and mechanisms
Year: 2014
Pulmonary alveolar proteinosis (PAP) in exogenous toxic alveolitis (ETA) patients
Source: International Congress 2015 – Occupational disease: clinical cases and series
Year: 2015
Use of acetylcysteinein the treatment of patients with exogenic allergic alveolitis (EAA)
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Safety of sputum induction (SI) in interstitial lung disease (ILD)
Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease
Year: 2007
House dust mites (HDM) natural exposure and alpha1 –acid glycoprotein (alpha1-AGP) level in expired air condensates (EAC) and nasal lavage fluid (NLF) of children with bronchial asthma (BA) and allergic rhinitis (AR)
Source: International Congress 2014 – Environment and mechanisms
Year: 2014
Enhanced expression of interleukin 8 (CXCL8) in cystic fibrosis (CF) airway epithelial (AE) cells
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP)
Source: International Congress 2014 – ILDs 2
Year: 2014
Radiological and morphological patterns in pneumoconiosis (PC) and exogenous toxic alveolitis (ETA)
Source: Eur Respir J 2001; 18: Suppl. 33, 528s
Year: 2001
mRNA expression of YY1, TNF-α a TGF-β in lung samples gained by transbronchial biopsies (TBB) in patients with different interstitial lung diseases (ILDs)
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Studies on apoptosis of alveolar lymphocytes (AL) in exogenous allergic alveolitis (EAA)
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Detection of anti DFS70 antibodies in patients with interstitial lung disease (ILD) with and without connective tissue disease (CTD)
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Difference in immunological aspects of inflammation in idiopathic pulmonary fibrosis (IPF) and exogenous toxic alveolitis (ETA)
Source: Eur Respir J 2003; 22: Suppl. 45, 121s
Year: 2003
Prevalence of occupational and environmental exposures in Australian patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Occupational asthma, abestosis and silicosis
Year: 2014
Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Enhanced interleukin-18 expression in rodent models of quartz induced fibrosis
Source: International Congress 2015 – Occupational and environmental effects: in vitro and animal models
Year: 2015
Clara cell secretory protein (CC16) and surfactant protein D (SPD) in sputum supernatant in severe refractory asthma (SRA)
Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Year: 2012
Levels of cytokines, sCD31 and expression of CD38 in patients with bronchial asthma of various severity out of a disease exacerbation
Source: International Congress 2014 – Biomarkers of asthma and clinical immunology
Year: 2014
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept